Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.63 |
| ▸ | MAOB | P27338 | 13/20 | 0.63 |
| ▸ | PRKCI | P41743 | 1/20 | 0.63 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538267 | 0.87 | CASP1 (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL5543621 | 0.83 | MAOA (0.55) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL929312 | 0.78 | CASP1 (0.78) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL1798900 | 0.78 | MAOA (0.67) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL228128 | 0.78 | MAOA (1.00) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL8131108 | 0.78 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL207834 | 0.78 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL5858951 | 0.78 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL1027718 | 0.78 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL315147 | 0.78 | MAOA (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0574906-B1 | Piperazine and homopiperazine derivatives, pharmaceutical compositions containing them and process for preparing the same | NISSHIN FLOUR MILLING CO (JP) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAOA 2885/4885MAOB 2140/4885PRKCI 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.